Day: November 16, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51206-40-7,1,4-Dibromoisoquinoline,as a common compound, the synthetic route is as follows.,51206-40-7

A solution of 1 ,4- dibromoisoquinoline (230 mg, 0.8 mmol), 4-methoxybenzene sulfonamide (300 mg, 1.6 mmol), Cul (60 mg, 0.3 mmol), K2C03 (1.18 g, 8.5 mmol), and N1 ,N2 -dimethylethane-1 ,2-diamine (142 mg, 1.6 mmol) in MeCN (6 ml.) was heated at 70 C for 7 days. On completion, the reaction mixture was quenched with H20 (20 ml_), and the yellow-colored solid was collected by filtration. The collected solid was washed with Et20 (10 ml.) and dried to yield the title compound.

The synthetic route of 51206-40-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; MOORE, Terry; LAZZARA, Phillip; DAVID, Brian; RICHARDSON, Benjamin; JAIN, Atul, D.; (87 pag.)WO2019/195348; (2019); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34784-04-8,5-Bromoisoquinoline,as a common compound, the synthetic route is as follows.

To a solution of n-butyllithium (19.3 mL of 2.5 M in hexanes, 48 mmol) in a mixture of ether (80 mL) and THF (80 mL) at -78¡ã C. was added dropwise a solution of bromoisoquinoline (5.0 g, 24 mmol) in THF (10 mL). The reaction mixture was stirred at -78¡ã C. under argon for 30 minutes. Following the general procedures described by Pearson, et al., in J. Heterocycl. Chem., Vol. 6 (2), pp. 243-245 (1969), a solution of DMF (3.30 g, 45 mmol) in THF (10 mL) was cooled to -78¡ã C. and quickly added to the isoquinolyllithium solution. The mixture was stirred at -78¡ã C. for 15 minutes. Ethanol (20 mL) was added followed by saturated NH4Cl solution. The resulting suspension was warmed to room temperature. The organic layer, combined with the ether extraction layer, was dried over Na2SO4. A pale yellow solid (2.4 g, 15 mmol, 64percent yield) was obtained from chromatography (SiO2 Type-H, 50percent EtOAc in hexanes) and recrystallization (ethanol): mp 114-116¡ã C.; 1H NMR (DMSO-d6) delta 10.40 (s, 1H), 9.44 (s, 1H), 8.85 (d, 1H, J=6.0 Hz), 8.69(d, 1H, J=6.0 Hz), 8.45 (m, 2H), 7.90 (t, 1H, J=7.2 Hz); 13C NMR (DMSO-d6) delta 194.23, 153.5, 146.2, 140.2, 135.2, 132.6, 130.2, 128.6, 127.5, and 117.2. Anal. Calcd. for C10H7NO.0.05H2O: C, 75.99; H, 4.53; N, 8.86. Found: C, 75.98, H, 4.66; N, 8.68., 34784-04-8

The synthetic route of 34784-04-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DarPharma, Inc.; US2007/155720; (2007); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.18881-17-9,(S)-(1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol,as a common compound, the synthetic route is as follows.,18881-17-9

Step A: Benzyl (3S)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate This compound is obtained using a protocol from the literature (R. B. Kawthekar et al South Africa Journal of Chemistry 63, 195, 2009) starting from 15 g of (3S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethanol (91.9 mmol) in the presence of benzyl chloroformate and triethylamine in solution in dichloromethane. After purification by chromatography over silica gel using petroleum ether and ethyl acetate as eluants, the title product is obtained in the form of an oil. 1H NMR: delta (300 MHz; DMSO-d6; 300K): 7.33 (m, 5H, aromatic Hs, O-benzyl); 7.15 (s, 4H, aromatic Hs, H tetrahydroisoquinoline); 5.13 (s, 2H, CH2-Ph); 4.73 (d, 1H, H tetrahydroisoquinoline); 4.47 (m, H, CH2OH); 4.36 (m, 1H, H tetrahydroisoquinoline); 4.28 (d, 1H, H tetrahydroisoquinoline); 3.39 (dd, 1H, CH2OH); 3.23 (dd, 1H, CH2OH); 2.93 (dd, 1H, H tetrahydroisoquinoline); 2.86 (dd, 1H, H tetrahydroisoquinoline) IR: nu: OH: 3416 cm-1; nu: C-H: 754 cm-1

The synthetic route of 18881-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; LE TIRAN, Arnaud; LE DIGUARHER, Thierry; STARCK, Jerome-Benoit; HENLIN, Jean-Michel; GUILLOUZIC, Anne-Francoise; DE NANTEUIL, Guillaume; GENESTE, Olivier; FEJES, Imre; TATAI, Janos; NYERGES, Miklos; DAVIDSON, James Edward Paul; MURRAY, James Brooke; CHEN, I-Jen; DURAND, Didier; US2015/31673; (2015); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.374554-54-8,5-Amino-1-chloroisoquinoline,as a common compound, the synthetic route is as follows.

EXAMPLE 64B N-[(4-bromophenyl)methyl]-N’-(1-chloroisoquinolin-5-yl)urea The product from Example 64A (520 mg, 2.91 mmol) in toluene (8 mL) was treated with 1-bromo-4-(isocyanatomethyl)benzene (0.41 mL, 2.93 mmol) with stirring and then the mixture was heated at 90 C. for 2 hours. The mixture was allowed to cool to room temperature, filtered, the filter cake washed with toluene, and air-dried to provide the title compound as an off-white solid (717 mg, 63%). 1H NMR (300 MHz, DMSO-d6) delta 8.89 (s, 1H), 8.34-8.37 (m, 2H), 8.00 (dd, J=6.1 Hz, 0.7 Hz, 1H), 7.92-7.95 (m, 1H), 7.73 (t, J=8.1, 1H), 7.53-7.56 (m, 2H), 7.30-7.33 (m, 2H), 7.12 (t, J=5.8 Hz, 1H), 4.35 (d, J=5.8 Hz, 2H); MS (ESI+) m/z 390/392 (M+H+, 35Cl/37Cl)., 374554-54-8

As the paragraph descriping shows that 374554-54-8 is playing an increasingly important role.

Reference£º
Patent; Abbott Laboratories; US6933311; (2005); B2;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

1198-30-7, 1-Isoquinolinecarbonitrile is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1198-30-7, A solution of isoquinoline-1-carbonitrile (Intemediate H1) (commercially available from Aldrich) (4.40 g, 28.5 mmol) in THF at 0 C. was treated with methylmagnesium bromide (20 mL, of a 3M soln in ether) for 3 h. (see procedure found in Vacher, B. et al J. Med. Chem. 1998 41, 5070; incorporated herein by reference). The mixture was quenched with a sat. solution of NH4Cl and stirred for 3 h at rt. The aqueous layer was basified with NaOH and extracted with ethyl acetate. The organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The material was purified by chromatography on silica gel with 10% ethyl acetate: hexane to give 1-isoquinolin-1-yl-ethanone (Intermediate H2) 3.65g (75%). A mixture of 4-iodo-1-tritylimidazole (commercially available) (15.5 g, 35.4 mmol) in dichloromethane (80 mL) at 20 C. was treated with ethyl magnesium bromide (12.0 mL, 36 mmol, 3M in ether) and allowed to react for 1 h. A solution of 1-isoquinolin-1-yl-ethanone (Intermediate H2) (3.65 g, 21.3 mmol) in dichloromethane (20 mL) was added via addition funnel at 20 C. and stirred for 16 h. The mixture was quenched with sat. ammonium chloride (100 mL) and diluted with dichloromethane. The residue was isolated in an aqueous workup. The product was extracted with CH2Cl2 and purified by chromatography on silica gel with 5% NH3-MeOH: CH2Cl2 to give 1-isoquinolin-1-yl-1-(1-trityl-1H-imidazol-4-yl)-ethanol (Intermediate H3) as a solid. 1-Isoquinolin-1-yl-1-(1-trityl-1H-imidazol-4-yl)-ethanol (Intermediate H3) was subjected to TFA: trifluoroacetic acid, Pd/C under hydrogen similar to the catalytic reduction procedure of Method D to remove the trityl group and produced 1-1H-imidazol-4-yl)-isoquinolin-1-yl ethanol (Intermediate H4). 1-1H-Imidazol-4-yl)-isoquinolin-1-yl ethanol (Intermediate H4). (21 mmol) in dichloromethane (100 mL) was treated with triethylamine (24.0 mL, 172 mmol) at 0 C. Methanesulfonyl chloride (6.1 mL, 75 mmol) was added via syringe and the mixture was stirred for 2 h. The mixture was subjected to an aqueous work-up. The crude material was purified by chromatography on silica gel with 20% EtOAc: hexane to 5% NH3-MeOH: dichloromethane to give 1-[1-(1-methanesulfonyl-1H-imidazol-4-yl)-vinyl]-isoquinoline (Intermediate H5) 3 g. 1-[1-(1-Methanesulfonyl-1H-imidazol-4-yl)-vinyl]-isoquinoline (Intermediate H5) was subjected to the catalytic reduction procedure found in Method D to produce 1-[1-(1-methanesulfonyl-1H-imidazol-4-yl)-ethyl]-isoquinoline (Intermediate H6). Methanesulfonyl-1H-imidazol-4-yl)-ethyl]-isoquinoline (Intermediate H6) in ethanol and 2M HCl was heated at reflux for 18 h. The mixture was cooled to rt and basified with NaOH solid. The aqueous layer was extracted with isopropanol:chloroform (3:1). The organic fractions were dried over MgSO4, filtered and concentrated onto silica gel. The product, 1-[1-(1H-imidazol-4-yl)-ethyl]-isoquinoline (Intermediate H7) was eluted from a column of silica gel with 3 to 5% NH3-MeOH: CH2Cl2. 1-[1-(1H-Imidazol-4-yl)-ethyl]-isoquinoline (Intermediate H7) was subjected to the appropriate process steps in Method A to produce 4-(1-isoquinolin-1-yl-ethyl)-1,3-dihydro-imidazole-2-thione (Compound 13) 1H NMR (300 MHz, DMSO-d6): delta11.9 (s, 1H), 11.6 (s, 1H), 8.42 (dd, J=5.4, 2.7 Hz, 1H), 8.31 (d, J=8.1 Hz, 1H), 7.96 (d, J=8.1 Hz, 1H), 7.78-7.64 (m, 3H), 6.40 (s, 1H), 5.0 (q, J=6.9 Hz, 1H), 1.59 (d, J=6.9 Hz, 3H).

1198-30-7 1-Isoquinolinecarbonitrile 306057, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Allergan, Inc.; US2006/69143; (2006); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4494-18-2,1-Isoquinolinecarboxaldehyde,as a common compound, the synthetic route is as follows.

The compound (80 mg) obtained in Example 47-3 was dissolved in methanol (5.0 ml) and added with the compound (59.9 mg) obtained in Example 63-1, followed by the addition of sodium cyanoborohydride (35.9 mg). Then, the reaction solution was adjusted to about pH 5 with acetic acid, followed by stirring at room temperature for 14 hours. The reaction solution was added with a saturated aqueous sodium bicarbonate solution and then extracted with chloroform. The organic layer was washed with saturated saline solution and then dried with anhydrous sodium sulfate. Subsequently, the solvent was distilled off. The resulting crude product was purified through silica gel column chromatography (chloroform/methanol) and treated with hydrochloric acid, thereby obtaining hydrochloride (97.1 mg) of the subject compound as a white solid. MS(FAB,Pos.):m/z=561[M+H]+1H-NMR(500MHz,DMSO-d6):delta=0.87(6H,t,J=7.4Hz),1.67-1.78(4H,m),2.86-2.93(4H,m),3.92(2H,s),4.25-4.26(2H,m),4.36(2H,s),4.78(2H,brs),7.57-7.65(6H,m),7.81-7.86(4H,m),7.95(1H,brs),8.11(1H,brs),8.23(1H,brs),8.48-8.52(1H,m),8.62(1H,d,J=6.2Hz),10.34(1H,s),10.48(1H,brs).

4494-18-2, As the paragraph descriping shows that 4494-18-2 is playing an increasingly important role.

Reference£º
Patent; Kureha Chemical Industry Co., Ltd.; EP1550657; (2005); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7651-81-2,Isoquinolin-3(2H)-one,as a common compound, the synthetic route is as follows.

Preparation 11; A mixture of 3-hydroxyisoquinoline (500 mg, 3.44 mmol) and ethyl methacrylate (1.29 mL, 10.3 mmol) in toluene (10 mL) in a sealed reaction vessel was heated at 170 C for 16 h. The reaction mixture was concentrated and the product purified by preparative HPLC. A fraction containing isomers A and B in a 3: 1 ratio (A: B), was obtained as an oil (284 mg, 32% yield). MS (E+) m/z : 260 (MH+) ; Liquid Chromatograph (“LC”) retention time (“Rt”): 2.41 min (broad). A second fraction containing isomers C and D in a 5: 1 ratio (C: D) was also obtained as a solid (502 mg, 56%). MS (E+) nzlz : 260 (MH+) ; LC retention time: 2.70 min (broad)., 7651-81-2

The synthetic route of 7651-81-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; WO2005/73221; (2005); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.84468-15-5,Isoquinoline-5-sulfonyl chloride,as a common compound, the synthetic route is as follows.

a) (S)-4-{2-[4-(Isoquinoline-5-sulfonylamino)-pcarboxylic acid tert-butyl ester(S)-4-[2-(4-Amino-phenyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (150 mg) was dissolved in tetrahydrofuran at room temperature before treatment withtriethylamine (129.8 mu) and isoquinoline-5-sulfonyl chloride (141.4 mg), the reaction mixture was then warmed to 50 C and stirred for 6 hours. Upon evaporation of the solvent in vacuo the residue was purified by flash column chromatography (Si02; hexane/EtOAc 3: 1) to afford title compound (S)-4- {2-[4-(isoquinoline-5-sulfonylamino)-phenyl]-ethyl} -2,2-dimethyl-oxazolidine- 3-carboxylic acid tert-butyl ester (155 mg) as a white solid. MS (ISP): 512.3 ([M+H]+). b) Isoquino line-5 -sulfonic acid [4-((S)-3 -amino-4-hydroxy-butyl)-phenyl] -amide

84468-15-5, The synthetic route of 84468-15-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; GALLEY, Guido; NORCROSS, Roger; POLARA, Alessandra; WO2011/57973; (2011); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

105627-79-0, Isoquinoline-5-sulfonyl chloride hydrochloride is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 17 In 100 ml of ice water was dissolved 8.8 g of 5-isoquinolinesulfonyl chloride hydrochloride, and the pH of the solution was adjusted to 6 with a saturated aqueous sodium hydrogencarbonate solution, followed by extraction with 100 ml of dichloromethane. The dichloromethane layer was added dropwise to a 100 ml of dichloromethane solution containing 5.30 g of N-hexyl-2-hydroxypropylamine and 4.0 g of triethylamine over a period of 20 minutes while cooling with ice. The mixture was stirred at a temperature of 15 C to 20 C for 2 hours, washed with water, and dried with anhydrous magnesium sulfate. Then, the dichloromethane was removed under reduced pressure to obtain an oily residue. The thus obtained oily residue was subjected to purification by silica gel column chromatography (Wacogel C-200, 200 g; solvent: a 2 % methanol solution in chloroform) to obtain 9.02 g of N-hexyl-N-(2-hydroxypropyl)-5-isoquinolinesulfonamide.

105627-79-0, 105627-79-0 Isoquinoline-5-sulfonyl chloride hydrochloride 13116932, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Asahi Kasei Kogyo Kabushiki Kaisha; EP287696; (1988); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.84468-15-5,Isoquinoline-5-sulfonyl chloride,as a common compound, the synthetic route is as follows.

EXAMPLE 9 In 30 ml of water was dissolved 3.9 g of 1-amidinopiperazine sulfate, and 60 ml of tetrahydrofuran solution containing 4.1 g of 5-isoquinolinesulfonyl chloride and 1N sodium hydroxide was added dropwise under cooling with ice so that the pH of the solution maintain the range from 8 to 8.5. After the dropwise addition, the mixture solution was stirred for one hour. The crystalline residue was discarded, and the pH of the aqueous layer was adjusted to 1 with an aqueous diluted hydrochloric acid solution. The crystalline residue was discarded, and the pH of the aqueous layer was adjusted to 13 with a 5N aqueous sodium hydroxide solution. The crystals precipitated were separated by filtration, and the crystalline residue obtained was dissolved with an aqueous diluted hydrochloric acid solution. The pH of the solution was adjusted to 13.5 with a 2N aqueous sodium hydroxide solution. The crystals precipitated were separated by filtration, the crystalline residue was washed with water, methanol and ethylether and condensed to dryness to give 4.84 g of 4-amidino-1-(5-isoquinolinesulfonyl)piperazine, i.e., Compound (44) in a yield of 84%. Mass spectrum (m/e): 319, 302, 278 and 221. NMR spectrum (DMSO-d6, D2 SO4): 2.6~3.7 (8H), 7.7~8.3 (1H), 8.4~8.9 (4H) and 9.8 (1H). IR spectrum (numax, cm-1): 3320, 1675, 1590 and 1170., 84468-15-5

The synthetic route of 84468-15-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Asahi Kasei Kogyo Kabushiki Kaisha; Hidaka; Hiroyoshi; US4634770; (1987); A;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem